FR16C0014I2 - Vaccin contre le virus de la fievre du nil - Google Patents

Vaccin contre le virus de la fievre du nil

Info

Publication number: FR16C0014I2
Authority: FR; France
Prior art keywords: fever virus; virus vaccine; nile fever; nile; vaccine
Prior art date: 2001-04-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR16C0014C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Boehringer Ingelheim Animal Health France SAS

Boehringer Ingelheim Animal Health USA Inc

Original Assignee

Merial SAS

Merial Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-06

Filing date

2016-04-19

Publication date

2016-09-09

2016-04-19 Application filed by Merial SAS, Merial Inc filed Critical Merial SAS

2016-05-27 Publication of FR16C0014I1 publication Critical patent/FR16C0014I1/fr

2016-09-09 Application granted granted Critical

2016-09-09 Publication of FR16C0014I2 publication Critical patent/FR16C0014I2/fr

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Zoology (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
Mycology (AREA)
Plant Pathology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

FR16C0014C 2001-04-06 2016-04-19 Vaccin contre le virus de la fievre du nil Active FR16C0014I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0104737A FR2823222B1 (fr)	2001-04-06	2001-04-06	Vaccin contre le virus de la fievre du nil
PCT/FR2002/001200 WO2002081621A2 (fr)	2001-04-06	2002-04-05	Vaccin contre le virus de la fievre du nil

Publications (2)

Publication Number	Publication Date
FR16C0014I1 FR16C0014I1 (fr)	2016-05-27
FR16C0014I2 true FR16C0014I2 (fr)	2016-09-09

Family

ID=8862055

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
FR0104737A Expired - Lifetime FR2823222B1 (fr)	2001-04-06	2001-04-06	Vaccin contre le virus de la fievre du nil
FR16C0014C Active FR16C0014I2 (fr)	2001-04-06	2016-04-19	Vaccin contre le virus de la fievre du nil

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
FR0104737A Expired - Lifetime FR2823222B1 (fr)	2001-04-06	2001-04-06	Vaccin contre le virus de la fievre du nil

Country Status (22)

Country	Link
EP (2)	EP2979705B1 (fr)
JP (1)	JP4426761B2 (fr)
AU (1)	AU2002307971B2 (fr)
BE (1)	BE2016C021I2 (fr)
BR (1)	BRPI0208896B1 (fr)
CA (1)	CA2448796C (fr)
CY (2)	CY1117676T1 (fr)
DK (1)	DK1377660T3 (fr)
ES (2)	ES2767413T3 (fr)
FR (2)	FR2823222B1 (fr)
HK (2)	HK1061868A1 (fr)
HU (2)	HU230122B1 (fr)
IL (3)	IL158204A0 (fr)
LT (1)	LTC1377660I2 (fr)
LU (1)	LU93048I2 (fr)
MX (1)	MXPA03008998A (fr)
NL (1)	NL300806I2 (fr)
PL (2)	PL210306B1 (fr)
RU (1)	RU2283138C2 (fr)
SI (1)	SI1377660T1 (fr)
WO (1)	WO2002081621A2 (fr)
ZA (1)	ZA200307620B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2004521867A (ja)	2000-10-27	2004-07-22	イミュノ−アールエックス，インコーポレイテッド	免疫抑制された患者のためのワクチン免疫療法
RS53184B (en) *	2001-07-27	2014-06-30	Zoetis W Llc	COMPOSITION OF VACCINES FOR ADMINISTRATION FOR PREVENTING OR DETERMINING WEST NIL ENCEPHALITIS IN EQUID
CA2510229A1 (fr) *	2002-12-13	2004-07-08	Aventis Pasteur, Inc.	Production du virus alvac sur des cellules souches embryonnaires d'oiseaux
EP1626708B1 (fr)	2003-05-23	2017-11-29	Novartis Vaccines and Diagnostics, Inc.	Reactifs immunogenes provenant du virus du nil occidental
WO2006029300A2 (fr)	2004-09-09	2006-03-16	Research Development Foundation	Variants de flavivirus ayant une variation phenotypique et les compositions immunogeniques correspondantes
WO2007064802A1 (fr)	2005-12-02	2007-06-07	The Mount Sinai Medical Center Of New York University	Virus chimeriques presentant des proteines de surface non natives et leurs utilisations
EP2334327B1 (fr)	2008-08-29	2016-01-06	Boehringer Ingelheim Vetmedica, Inc.	Vaccin contre le virus du nil occidental
ES2550179T3 (es)	2009-02-05	2015-11-05	Icahn School Of Medicine At Mount Sinai	Virus quiméricos de la enfermedad de Newcastle y usos de los mismos
US8741311B2 (en)	2009-03-27	2014-06-03	Academia Sinica	Methods and compositions for immunization against virus
US9539320B2 (en)	2009-05-15	2017-01-10	Irx Therapeutics, Inc.	Vaccine immunotherapy
TWI537385B (zh)	2010-11-04	2016-06-11	中央研究院	產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
RU2506093C1 (ru) *	2012-12-06	2014-02-10	Государственное научное учреждение Якутский научно-исследовательский институт сельского хозяйства Российской академии сельскохозяйственных наук	Способ специфической профилактики ринопневмонии, сальмонеллезного аборта и мыта лошадей ассоциированной вакциной в условиях табунного содержания
GEP20196976B (en)	2013-03-14	2019-06-10	Sloan Kettering Cancer Center Memorial	Newcastle disease viruses and uses thereof
CA2940570A1 (fr)	2014-02-27	2015-09-03	Viralytics Limited	Therapie combinee pour le traitement du cancer
JOP20190256A1 (ar)	2017-05-12	2019-10-28	Icahn School Med Mount Sinai	فيروسات داء نيوكاسل واستخداماتها

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2909462A (en)	1955-12-08	1959-10-20	Bristol Myers Co	Acrylic acid polymer laxative compositions
US5110587A (en)	1981-12-24	1992-05-05	Health Research, Incorporated	Immunogenic composition comprising synthetically modified vaccinia virus
US5338683A (en)	1981-12-24	1994-08-16	Health Research Incorporated	Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5505941A (en)	1981-12-24	1996-04-09	Health Research, Inc.	Recombinant avipox virus and method to induce an immune response
US4722848A (en)	1982-12-08	1988-02-02	Health Research, Incorporated	Method for immunizing animals with synthetically modified vaccinia virus
US5174993A (en)	1981-12-24	1992-12-29	Health Research Inc.	Recombinant avipox virus and immunological use thereof
US4603112A (en)	1981-12-24	1986-07-29	Health Research, Incorporated	Modified vaccinia virus
US4769330A (en)	1981-12-24	1988-09-06	Health Research, Incorporated	Modified vaccinia virus and methods for making and using the same
US4745051A (en)	1983-05-27	1988-05-17	The Texas A&M University System	Method for producing a recombinant baculovirus expression vector
EP0173552B1 (fr)	1984-08-24	1991-10-09	The Upjohn Company	Composés recombinants d'ADN et l'expression de polypeptides comme le tPA
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
US4963481A (en)	1985-12-18	1990-10-16	Genetics Institute Inc	Promoter system
DE3730599A1 (de)	1986-09-12	1988-07-07	Genentech Inc	Verfahren zur kontinuierlichen herstellung von heterologen proteinen in eukaryontischen wirtszellen
DE3743138A1 (de)	1987-12-18	1989-09-14	Mayr Christian Gmbh & Co Kg	Schleifringlose, elektromagnetische ueberlastkupplung
MY109299A (en) *	1990-08-15	1996-12-31	Virogenetics Corp	Recombinant pox virus encoding flaviviral structural proteins
DE69233158T2 (de)	1991-03-07	2004-05-13	Connaught Technology Corp., Greenville	Gentechnologisch hergestellter stamm für impfstoffe
US5843456A (en)	1991-03-07	1998-12-01	Virogenetics Corporation	Alvac poxvirus-rabies compositions and combination compositions and uses
US5382425A (en)	1992-01-13	1995-01-17	Syntro Corporation	Recombinant swinepox virus
FR2702373B1 (fr)	1993-03-08	1996-06-07	Rhone Merieux	Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
EP0668355B1 (fr)	1993-12-20	1999-04-07	Akzo Nobel N.V.	Vaccin pour protéger des chevaux contre des infections du virus de l'herpes équin
FR2728794B1 (fr)	1994-12-30	1997-03-21	Rhone Merieux	Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
FR2728795B1 (fr)	1994-12-30	1997-03-21	Rhone Merieux	Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
CA2214029A1 (fr)	1995-04-25	1996-10-31	Magda Marquet	Formulations en ampoule unidose de complexes adn/lipides
WO1998000166A1 (fr)	1996-07-03	1998-01-08	Merial, Inc.	ADENOVIRUS CANIN DE RECOMBINAISON (ACR) CONTENANT DE l'ADN EXOGENE
FR2751225B1 (fr)	1996-07-19	1998-11-27	Rhone Merieux	Formule de vaccin polynucleotidique aviaire
FR2751227B1 (fr)	1996-07-19	1998-11-27	Rhone Merieux	Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751226B1 (fr)	1996-07-19	1998-11-27	Rhone Merieux	Formule de vaccin polynucleotidique contre les pathologies du cheval
AU4992197A (en)	1996-10-11	1998-05-11	Regents Of The University Of California, The	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
JP4504464B2 (ja) *	1997-02-28	2010-07-14	サノフィパスツールバイオロジクスカンパニー	キメラフラビウイルスワクチン
US7227011B2 (en) *	1998-06-04	2007-06-05	United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention	Nucleic acid vaccines for prevention of flavivirus infection
US6294176B1 (en)	1998-07-10	2001-09-25	Schering-Plough Veterinary Corp.	Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
US6416763B1 (en) *	1998-08-28	2002-07-09	Hawaii Biotechnology Group, Inc.	Recombinant nonstructural protein subunit vaccine against flaviviral infection
US6645740B1 (en)	1999-06-10	2003-11-11	Merial Limited	Nucleic acids encodings equine GM-CSF
WO2000077043A2 (fr)	1999-06-10	2000-12-21	Merial	Vaccins adn pour animaux de compagnie et de sport
FR2796397B1 (fr)	1999-07-16	2006-09-01	Merial Sas	Genes de calicivirus felin et vaccins notamment vaccins recombines

2001
- 2001-04-06 FR FR0104737A patent/FR2823222B1/fr not_active Expired - Lifetime
2002
- 2002-04-05 EP EP15162832.8A patent/EP2979705B1/fr not_active Expired - Lifetime
- 2002-04-05 ES ES15162832T patent/ES2767413T3/es not_active Expired - Lifetime
- 2002-04-05 MX MXPA03008998A patent/MXPA03008998A/es active IP Right Grant
- 2002-04-05 AU AU2002307971A patent/AU2002307971B2/en not_active Expired
- 2002-04-05 BR BRPI0208896A patent/BRPI0208896B1/pt active IP Right Grant
- 2002-04-05 JP JP2002579985A patent/JP4426761B2/ja not_active Expired - Lifetime
- 2002-04-05 ES ES02759818.4T patent/ES2566044T3/es not_active Expired - Lifetime
- 2002-04-05 DK DK02759818.4T patent/DK1377660T3/en active
- 2002-04-05 WO PCT/FR2002/001200 patent/WO2002081621A2/fr active Search and Examination
- 2002-04-05 CA CA2448796A patent/CA2448796C/fr not_active Expired - Lifetime
- 2002-04-05 RU RU2003132455/13A patent/RU2283138C2/ru active
- 2002-04-05 HU HU0401868A patent/HU230122B1/hu active Protection Beyond IP Right Term
- 2002-04-05 EP EP02759818.4A patent/EP1377660B1/fr not_active Expired - Lifetime
- 2002-04-05 PL PL391444A patent/PL210306B1/pl unknown
- 2002-04-05 SI SI200231069A patent/SI1377660T1/sl unknown
- 2002-04-05 PL PL365210A patent/PL207584B1/pl unknown
- 2002-04-05 IL IL15820402A patent/IL158204A0/xx unknown
2003
- 2003-09-30 ZA ZA2003/07620A patent/ZA200307620B/en unknown
- 2003-10-01 IL IL158204A patent/IL158204A/en active IP Right Grant
2004
- 2004-07-02 HK HK04104755.3A patent/HK1061868A1/zh not_active IP Right Cessation
- 2004-07-02 HK HK16106775.0A patent/HK1219412A1/zh not_active IP Right Cessation
2007
- 2007-08-14 IL IL185263A patent/IL185263A0/en active IP Right Grant
2015
- 2015-09-18 HU HUS1500047C patent/HUS1500047I1/hu unknown
2016
- 2016-04-06 CY CY20161100275T patent/CY1117676T1/el unknown
- 2016-04-19 FR FR16C0014C patent/FR16C0014I2/fr active Active
- 2016-04-20 LT LTPA2016011C patent/LTC1377660I2/lt unknown
- 2016-04-20 NL NL300806C patent/NL300806I2/nl unknown
- 2016-04-26 LU LU93048C patent/LU93048I2/fr unknown
- 2016-04-26 BE BE2016C021C patent/BE2016C021I2/fr unknown
- 2016-05-20 CY CY2016018C patent/CY2016018I1/el unknown

Also Published As

Publication number	Publication date
FR2823222A1 (fr)	2002-10-11
PL210306B1 (pl)	2011-12-30
CA2448796C (fr)	2012-11-20
IL158204A (en)	2013-03-24
JP4426761B2 (ja)	2010-03-03
ZA200307620B (en)	2005-07-27
EP1377660A2 (fr)	2004-01-07
ES2566044T3 (es)	2016-04-08
MXPA03008998A (es)	2004-10-15
CA2448796A1 (fr)	2002-10-17
HUP0401868A2 (hu)	2004-12-28
BE2016C021I2 (fr)	2021-03-23
AU2002307971B2 (en)	2008-01-17
EP2979705A1 (fr)	2016-02-03
CY2016018I2 (el)	2016-12-14
EP2979705B1 (fr)	2019-10-23
LTC1377660I2 (lt)	2017-04-25
WO2002081621A2 (fr)	2002-10-17
ES2767413T3 (es)	2020-06-17
JP2004531521A (ja)	2004-10-14
LU93048I2 (fr)	2016-06-27
IL185263A0 (en)	2008-01-06
PL365210A1 (en)	2004-12-27
DK1377660T3 (en)	2016-03-29
HK1219412A1 (zh)	2017-04-07
PL207584B1 (pl)	2011-01-31
EP1377660B1 (fr)	2016-01-13
NL300806I2 (fr)	2016-06-09
BR0208896A (pt)	2004-07-20
IL158204A0 (en)	2004-05-12
RU2283138C2 (ru)	2006-09-10
CY2016018I1 (el)	2016-12-14
HUP0401868A3 (en)	2011-06-28
SI1377660T1 (sl)	2016-05-31
FR2823222B1 (fr)	2004-02-06
HK1061868A1 (zh)	2004-10-08
RU2003132455A (ru)	2005-04-27
HUS1500047I1 (hu)	2017-03-28
FR16C0014I1 (fr)	2016-05-27
WO2002081621A3 (fr)	2003-02-20
BRPI0208896B1 (pt)	2016-06-07
CY1117676T1 (el)	2016-12-14
HU230122B1 (hu)	2015-08-28

Publication	Publication Date	Title
FR16C0014I2 (fr)	2016-09-09	Vaccin contre le virus de la fievre du nil
EP1603590A4 (fr)	2008-08-27	Vaccin contre le virus de la grippe
DK1407008T3 (da)	2009-04-27	Influenzavaccinesammens tning
FR14C0016I2 (fr)	2015-07-24	Vacccin west nile
EP1423141A4 (fr)	2005-08-03	Vaccin
DK1390066T3 (da)	2012-07-16	Vaccinesammensætning
NO20031483D0 (no)	2003-04-01	Vaksine
NO20024172L (no)	2002-11-01	Vaksine
EP1572124A4 (fr)	2007-11-28	Compositions de vaccin vhc e1e2
EP1307130A4 (fr)	2005-01-12	Vaccin contre le virus de l'immunodeficience humaine
DZ3219A1 (fr)	2001-02-22	Vaccin
NO20033882D0 (no)	2003-09-02	Vaksine
IS7831A (is)	2005-04-28	Bóluefni
EP1565583A4 (fr)	2007-11-21	Formulations de vaccin anti-vih
NO20040995L (no)	2004-04-29	Subenhetsvaksine for smittsom bukspyttkjertel-nekrosevirus
AU2002307971A1 (en)	2003-04-10	Vaccine against the nile fever virus
NO20033829L (no)	2003-10-27	Virusdrepende preparater
DE60328408D1 (de)	2009-08-27	Impfstoff
EP1389043A4 (fr)	2004-09-08	Vaccin contre le virus de la maladie de la fievre aphteuse
MA26270A1 (fr)	2004-09-01	Vaccin contre la variole
NO20051561D0 (no)	2005-03-23	Vaksine
EP1539938A4 (fr)	2007-11-28	Virus gb-b (gbv-b) chimerique
IS6184A (is)	2001-11-29	Bóluefni gegn ISA veiru
NO20012126D0 (no)	2001-04-30	HIV-vaksine
SI1436397T1 (sl)	2010-09-30	Cepivo proti virusu hepatitisa C